Novo Nordisk's steep stock decline has pushed it into deep undervaluation, now trading at attractive multiples below ...

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $439 millionCARVYKTI® demonstrated positive long-term outcomes in CARTITUDE-1 study with one-third of patients ...

Tesla faces challenges with EV tax credit removal, overhyped robotaxi timelines, and affordability risks. Read more on TSLA ...

This "first-of-its-kind" chew features 3 rd party certification and is designed to enhance blood flow and oxygen delivery for athletes ... key milestone achievements with our customers. Our CDMO ...

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $439 millionCARVYKTI® demonstrated positive long-term outcomes in CARTITUDE-1 study with one-third of patients remaini ...